JP2024542248A5 - - Google Patents

Info

Publication number
JP2024542248A5
JP2024542248A5 JP2024530029A JP2024530029A JP2024542248A5 JP 2024542248 A5 JP2024542248 A5 JP 2024542248A5 JP 2024530029 A JP2024530029 A JP 2024530029A JP 2024530029 A JP2024530029 A JP 2024530029A JP 2024542248 A5 JP2024542248 A5 JP 2024542248A5
Authority
JP
Japan
Prior art keywords
fluoro
quinoline
methyl
azabicyclo
hexane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024530029A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024542248A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/050558 external-priority patent/WO2023091746A1/en
Publication of JP2024542248A publication Critical patent/JP2024542248A/ja
Publication of JP2024542248A5 publication Critical patent/JP2024542248A5/ja
Pending legal-status Critical Current

Links

JP2024530029A 2021-11-22 2022-11-21 Fgfr阻害剤とkras阻害剤を含む併用療法 Pending JP2024542248A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163282017P 2021-11-22 2021-11-22
US63/282,017 2021-11-22
US202263317654P 2022-03-08 2022-03-08
US63/317,654 2022-03-08
US202263352491P 2022-06-15 2022-06-15
US63/352,491 2022-06-15
PCT/US2022/050558 WO2023091746A1 (en) 2021-11-22 2022-11-21 Combination therapy comprising an fgfr inhibitor and a kras inhibitor

Publications (2)

Publication Number Publication Date
JP2024542248A JP2024542248A (ja) 2024-11-13
JP2024542248A5 true JP2024542248A5 (cg-RX-API-DMAC7.html) 2025-12-03

Family

ID=84901810

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024530029A Pending JP2024542248A (ja) 2021-11-22 2022-11-21 Fgfr阻害剤とkras阻害剤を含む併用療法

Country Status (11)

Country Link
US (1) US20230226040A1 (cg-RX-API-DMAC7.html)
EP (1) EP4436578A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024542248A (cg-RX-API-DMAC7.html)
KR (1) KR20240122783A (cg-RX-API-DMAC7.html)
AU (1) AU2022389961A1 (cg-RX-API-DMAC7.html)
CA (1) CA3239205A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024001523A1 (cg-RX-API-DMAC7.html)
IL (1) IL312886A (cg-RX-API-DMAC7.html)
MX (1) MX2024006113A (cg-RX-API-DMAC7.html)
TW (1) TW202320792A (cg-RX-API-DMAC7.html)
WO (1) WO2023091746A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023283213A1 (en) * 2021-07-07 2023-01-12 Incyte Corporation Tricyclic compounds as inhibitors of kras
US20240101557A1 (en) * 2022-07-11 2024-03-28 Incyte Corporation Fused tricyclic compounds as inhibitors of kras g12v mutants
US20250114346A1 (en) * 2023-10-09 2025-04-10 Incyte Corporation Combination therapy using a kras g12d inhibitor and pd-1 inhibitor or pd-l1 inhibitor

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
ES2342240T3 (es) 1998-08-11 2010-07-02 Novartis Ag Derivados de isoquinolina con actividad que inhibe la angiogenia.
US6133031A (en) 1999-08-19 2000-10-17 Isis Pharmaceuticals Inc. Antisense inhibition of focal adhesion kinase expression
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
CN100391958C (zh) 2001-09-19 2008-06-04 安万特医药股份有限公司 化合物
PT1441737E (pt) 2001-10-30 2006-12-29 Dana Farber Cancer Inst Inc Derivados de estrutura como inibidores da actividade do receptor de tirosina cinase flt3
EP1456652A4 (en) 2001-11-13 2005-11-02 Dana Farber Cancer Inst Inc IMMUNOCELL ACTIVATION MODULATING SUBSTANCES AND USE METHOD THEREFOR
NZ534069A (en) 2002-01-22 2007-03-30 Warner Lambert Co 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones to be used to treat neurodegenerative disorders, viruses and cancer
PE20040522A1 (es) 2002-05-29 2004-09-28 Novartis Ag Derivados de diarilurea dependientes de la cinasa de proteina
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
AR042052A1 (es) 2002-11-15 2005-06-08 Vertex Pharma Diaminotriazoles utiles como inhibidores de proteinquinasas
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
ES2367430T3 (es) 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
PE20050952A1 (es) 2003-09-24 2005-12-19 Novartis Ag Derivados de isoquinolina como inhibidores de b-raf
RU2007123675A (ru) 2004-11-24 2008-12-27 Новартис АГ (CH) Комбинации ингибиторов jak
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
AU2008343932B2 (en) 2007-12-19 2013-08-15 Amgen Inc. Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
WO2010036959A2 (en) 2008-09-26 2010-04-01 Dana-Farber Cancer Institute Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
PA8852901A1 (es) 2008-12-22 2010-07-27 Lilly Co Eli Inhibidores de proteina cinasa
WO2010089411A2 (en) 2009-02-09 2010-08-12 Universite De La Mediterranee Pd-1 antibodies and pd-l1 antibodies and uses thereof
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
US20130022629A1 (en) 2010-01-04 2013-01-24 Sharpe Arlene H Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof
UY33227A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
US9163087B2 (en) 2010-06-18 2015-10-20 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against TIM-3 and PD-1 for immunotherapy in chronic immune conditions
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
KR102186969B1 (ko) 2010-10-25 2020-12-04 쥐원 쎄라퓨틱스, 인크. Cdk 억제제
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
KR101606250B1 (ko) 2011-03-23 2016-03-24 암젠 인크 Cdk 4/6 및 flt3의 융합된 트리사이클릭 이중 저해제
CA2876689C (en) 2012-06-13 2022-04-26 Incyte Corporation Substituted tricyclic compounds as fgfr inhibitors
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
PH12015502383B1 (en) 2013-04-19 2023-02-03 Incyte Holdings Corp Bicyclic heterocycles as fgfr inhibitors
WO2016064960A1 (en) 2014-10-22 2016-04-28 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
CA2976790C (en) 2015-02-20 2024-02-27 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
PE20231958A1 (es) 2015-07-30 2023-12-06 Macrogenics Inc Moleculas de union a pd-1 y metodos de uso de las mismas
US20170107216A1 (en) 2015-10-19 2017-04-20 Incyte Corporation Heterocyclic compounds as immunomodulators
MD3377488T2 (ro) 2015-11-19 2023-02-28 Incyte Corp Compuși heterociclici ca imunomodulatori
ES2916874T3 (es) 2015-12-17 2022-07-06 Incyte Corp Derivados de N-fenil-piridina-2-carboxamida y su uso como moduladores de la interacción proteína/proteína PD-1/PD-L1
CA3009474A1 (en) 2015-12-22 2017-06-29 Incyte Corporation Heterocyclic compounds as immunomodulators
ES2906460T3 (es) 2016-05-06 2022-04-18 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
EP3464279B1 (en) 2016-05-26 2021-11-24 Incyte Corporation Heterocyclic compounds as immunomodulators
SG11201811414TA (en) 2016-06-20 2019-01-30 Incyte Corp Heterocyclic compounds as immunomodulators
MA45669A (fr) 2016-07-14 2019-05-22 Incyte Corp Composés hétérocycliques utilisés comme immunomodulateurs
US20180057486A1 (en) 2016-08-29 2018-03-01 Incyte Corporation Heterocyclic compounds as immunomodulators
US10308644B2 (en) 2016-12-22 2019-06-04 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2018119236A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Triazolo[1,5-a]pyridine derivatives as immunomodulators
EP4223369A1 (en) 2016-12-22 2023-08-09 Incyte Corporation Immunomodulator compounds and methods of use
WO2018119221A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Pyridine derivatives as immunomodulators
WO2018119286A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Bicyclic heteroaromatic compounds as immunomodulators
WO2018119263A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds derivatives as pd-l1 internalization inducers
SMT202300065T1 (it) 2018-03-30 2023-05-12 Incyte Corp Composti eterociclici come immunomodulatori
RS66310B1 (sr) 2018-05-04 2025-01-31 Incyte Corp Čvrsti oblici inhibitora fgfr i procesi za njegovu pripremu
KR102956194B1 (ko) 2018-05-04 2026-04-23 인사이트 코포레이션 Fgfr 억제제의 염
CN112752756B (zh) 2018-05-11 2024-06-25 因赛特公司 作为PD-L1免疫调节剂的四氢-咪唑并[4,5-c]吡啶衍生物
CN121270550A (zh) 2020-04-16 2026-01-06 因赛特公司 稠合三环kras抑制剂
WO2023283213A1 (en) * 2021-07-07 2023-01-12 Incyte Corporation Tricyclic compounds as inhibitors of kras

Similar Documents

Publication Publication Date Title
US10676462B2 (en) Quinoline derivative
US7999006B2 (en) Methods of using MEK inhibitors
JP2021011495A5 (cg-RX-API-DMAC7.html)
TW202529768A (zh) 癌症治療的療法
RU2365588C2 (ru) Хиназолиновые соединения
IL295799A (en) Trophomyosin receptor kinase (trk) degradation compounds and methods of use
RU2497822C2 (ru) Селективные к bcl-2 агенты, вызывающие апоптоз, для лечения рака и иммунных заболеваний
JP2023522202A5 (cg-RX-API-DMAC7.html)
JP2019537571A5 (cg-RX-API-DMAC7.html)
JP2019535658A5 (cg-RX-API-DMAC7.html)
JP2019527731A (ja) Hbv感染の治療のための新規治療薬
JP2012501312A5 (cg-RX-API-DMAC7.html)
JP2017048219A5 (cg-RX-API-DMAC7.html)
JP2013508382A5 (cg-RX-API-DMAC7.html)
JP2005526723A5 (cg-RX-API-DMAC7.html)
CN1152870A (zh) 杂环化合物作为多巴胺d3配位体的用途
RU2008112221A (ru) Соединения ряда изоиндолимидов, их композиции и способы применения
JP2011509309A5 (cg-RX-API-DMAC7.html)
JP2019505595A5 (cg-RX-API-DMAC7.html)
CN103228643B (zh) 作为组胺h4受体配体的苯并唑衍生物
JP2018509442A (ja) Fgfr4阻害剤としてのホルミル化n−複素環式誘導体
RU2012141607A (ru) Производные аминоинданов, их получение и применение в терапии
JP2004508366A5 (cg-RX-API-DMAC7.html)
CN110433165A (zh) Akt和mek抑制剂化合物的组合及其使用方法
JP2004524279A5 (cg-RX-API-DMAC7.html)